Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Quoin Pharmaceuticals received EMA Orphan Drug Designation for its lead candidate QRX003 for the treatment of Peeling Skin Syndrome. The designation provides incentive benefits including scientific advice, fee reductions, and access to EU grants, plus 10 years of market exclusivity in Europe if marketing authorization is granted.
Key figures
- Drug Name
- QRX003
- Market exclusivity years eu
- 10
- Regulatory milestones count
- 8
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.